Approximately twice as many drugs in the central nervous system (CNS)
and psychiatric, musculoskeletal and pain, respiratory and gastrointestinal, oncology, miscellaneous, and small molecule categories
received a priority review in the United States as in Canada,
although the numbers in thefirst three categories were small.